Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;29(1):e12735.
doi: 10.1111/xen.12735. Epub 2022 Feb 15.

Invited commentary

Robert A Montgomery  1
Affiliations
Comment

Invited commentary

Robert A Montgomery. Xenotransplantation. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Yerly P, Rotman S, Regamey J, et al. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. Xenotransplantation. 2022;29(1):e12726. https://doi.org/10.1111/xen.12726
    1. Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: new approaches in prevention and management. Am J Transplant. 2018;18(3):3-17. http://doi.org/10.1111/ajt.14584
    1. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215-1226.
    1. Marks WH, Mamode N, Montgomery RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant. 2019;19(10):2876-2888.
    1. Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant. 2019;19(6):1671-1683.

LinkOut - more resources